DAWEX
With more than 80% of industrial data[1] remaining unused, the Data Act calls for the need of fundamental measures to regulate data circulation in order to make data more accessible for all. Granting consumers and companies the control over who accesses their data, for what purpose, is a pillar principle to future measures in order to unlock the richness of industrial data and build a regulated, fair European data economy. Dawex Data Exchange technology awards platform orchestrators the capability to keep control over the circulation of data through a secure, trusted data sharing and data exchange environment ensuring visibility of which data is being used, for which usage, under which terms.
In today’s economy where data has become a product with its own value, not limited to its usage, and the source of new revenue streams, Dawex technology allows organizations to create and gather new ecosystems around data exchange platforms that meet regulatory frameworks and addresses traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub , whose mission is to facilitate and accelerate secure data circulation between all economic stakeholders.
As the European Data Act stresses the critical importance of industrial data circulation in order to foster European data-driven innovation, Dawex technology has already demonstrated its operational and business value in more than 20 sectors such as agriculture, space, retail, agrifood, automotive, infrastructure, tourism, real estate and mobility by helping organizations in those industries address economical, social and environmental challenges.
The future Data Act is designed to harmonize rules on the fair access to and use of data generated in the EU across all economic sectors. The proposed measures encompass:
- Facilitating access to generated IoT data to boost data-driven innovative services development,
- Rebalancing SMEs’ negotiating power to prevent contractual misconducts in data exchange contracts,
- Allowing public sector bodies access to data held by companies in public emergencies situations,
- Defining new rules for data and cloud interoperability to simplify cloud and edge service providers switch,
- Safeguarding unlawful data access and transfer by non-EU governments.
Dawex Data Exchange solution provides all the means and capabilities for data providers, data users and data exchange service providers to implement the future Data Act principles by delivering the high level of flexibility, traceability, and control available to all parties involved in data exchange. Data products can be clearly defined, accessed, and exchanged under flexible and fully configurable licensing terms, free of charge or against compensation.
“The Data Act’s ambition is to ensure a fair and innovative European data economy by making data more available for reuse to stimulate data-driven innovation.” said Laurent Lafaye, co-CEO at Dawex. “Since its inception, Dawex has been committed to delivering cutting-edge data exchange technology to bring the perfect conditions for secure and compliant data sharing. Dawex Data Exchange solutions are already aligned to what the Data Act proposes.”
Available in white label, Dawex Data Exchange, Data Hub and Data Marketplace solutions are today the only solutions on the market to offer such easy, efficient and highly secure data exchange capabilities.
“The development of Data Exchange technology facilitates the circulation of data between all economic stakeholders, supporting the flexible deployment of data ecosystems and their interconnection.” said Fabrice Tocco, Dawex co-CEO. “The European Data Act is another critical milestone that confirms Dawex vision and its technological direction for data exchange, driving a strong data economy.”
About Dawex
Dawex is the leading technology company for data exchange , data marketplace and data hub . Dawex mission is to facilitate and accelerate secure data circulation between economic stakeholders, institutions and private organizations, contributing to the development of the data economy. Awarded Technology Pioneer by the World Economic Forum, Dawex is a member of Gaia-X and a co-founding member of the Data Exchange Association . Created in 2015, Dawex has offices in France and Canada, expanding business operations to Asia, North America and the Middle East.
[1] Source: European Commission
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom